SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-306217
Filing Date
2020-12-01
Accepted
2020-12-01 07:05:55
Documents
12
Period of Report
2020-11-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d22638d8k.htm   iXBRL 8-K 25426
  Complete submission text file 0001193125-20-306217.txt   148131

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kpti-20201125.xsd EX-101.SCH 3075
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20201125_lab.xml EX-101.LAB 18138
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20201125_pre.xml EX-101.PRE 11411
5 EXTRACTED XBRL INSTANCE DOCUMENT d22638d8k_htm.xml XML 3348
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 201359767
SIC: 2834 Pharmaceutical Preparations